Agios Pharm

Yahoo Finance • 2 days ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is schedul... Full story

Yahoo Finance • 8 days ago

Jefferies Group's Strategic Moves: Amazon.com Inc. Takes Center Stage with 2.28% Portfolio Impact

Insightful Analysis of Jefferies Group (Trades, Portfolio)'s Fourth Quarter 2024 13F Filing Warning! GuruFocus has detected 7 Warning Sign with JPM. Jefferies Group (Trades, Portfolio) recently submitted its 13F filing for the fourth qua... Full story

Yahoo Finance • 9 days ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Ar... Full story

Yahoo Finance • 9 days ago

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused – – Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adults w... Full story

Yahoo Finance • 10 days ago

Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now.In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against the other cheap biotech stocks. Biotech Stocks Face... Full story

Yahoo Finance • 16 days ago

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will... Full story

Yahoo Finance • 5 months ago

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the har... Full story

Yahoo Finance • 6 months ago

Agios Pharmaceuticals, Inc. (AGIO): Are Street Analysts Bullish on This Top Caligan Partner Holding Right Now?

We recently compiled a list of the Top 10 Holdings of Caligan Partners.In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against Caligan Partners' other top holdings. Founded in 2017, C... Full story

Yahoo Finance • 6 months ago

Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now?

We recently compiled a list of the Top 10 Holdings of Caligan Partners.In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against Caligan Partners' other top holdings. Founded in 2017, C... Full story

Yahoo Finance • 7 months ago

Here's What Analysts Are Forecasting For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Second-Quarter Results

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) just released its latest quarterly report and things are not looking great. The numbers were fairly weak, with revenue of US$8.6m missing analyst predictions by 7.4%, and (statutory) losses of US$1... Full story

Yahoo Finance • last year

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence; One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy Volunteers Study – – Company Expects to... Full story

Yahoo Finance • last year

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript November 2, 2023 Agios Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.64, expectations were $-1.69. Operator: Good day and thank you for s... Full story

Yahoo Finance • last year

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support Advancement to Phase 3 Portion of RISE UP – –... Full story

Yahoo Finance • last year

Agios Reports Business Highlights and Third Quarter 2023 Financial Results

– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease – – Completed Enrollment in Phase 3 ACTIVATE-KidsT Pediatric Study of Mitapivat in PK Deficiency; ACTIVATE-Kids Study Achieves >50%... Full story

Yahoo Finance • last year

Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call... Full story

Yahoo Finance • last year

Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present... Full story

Yahoo Finance • 2 years ago

Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023

CAMBRIDGE, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call... Full story

Yahoo Finance • 2 years ago

Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response

– Study’s Primary Efficacy Endpoint Achieved, with 46.2% of Patients in the 50 mg BID Mitapivat Arm and 50.0% of Patients in the 100 mg BID Mitapivat Arm Achieving a Hemoglobin Response, Compared to 3.7% of Patients in the Placebo Arm – –... Full story

Yahoo Finance • 2 years ago

Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress

– Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical Benefit of PYRUKYND® (mitapivat) on Hemoglobin, Hemolysis, Iron Overload and Patient-Reported Outco... Full story

Yahoo Finance • 2 years ago

Agios Reports Business Highlights and First Quarter 2023 Financial Results

– On Track for PYRUKYND® (mitapivat) Data Readouts of the Phase 2 Portion of the RISE UP Study in Sickle Cell Disease in Mid-2023 and the Phase 3 ENERGIZE and ENERGIZE-T Studies in Thalassemia in 2024 – U.S. PYRUKYND® Net Revenue of $5.6... Full story